---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-25-000012"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:49:44.402196+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirum reports 2024 net product sales $336.4M; guides 2025 sales $420M-$435M

## Summary
- 2024 net product sales $336.4M, up from $178.9M in 2023; LIVMARLI sales $213.3M, Bile Acid Medicines $123.1M.
- 2025 global net product sales guidance of $420M to $435M; expects positive cash flow.
- Volixibat VISTAS PSC study expected to complete enrollment H2 2025; topline data in 2026.
- Cash, equivalents and investments $292.8M as of Dec 31, 2024 (vs $286.3M end 2023).
- CTEXLI (chenodiol) approved in US for cerebrotendinous xanthomatosis; MRM-3379 Phase 2 in FXS expected in 2025.

## SEC filing metadata
- accession: 0001759425-25-000012
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000012/0001759425-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000012/mirm-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-25-000012
- JSON: https://secwatch.observer/filing/0001759425-25-000012.json
- Plain text: https://secwatch.observer/filing/0001759425-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.